Clinical Trial Results: Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Foster 100/6 mg NEXThaler to Foster 100/6 mg pMDI in patients with controlled asthma; results completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Foster 100/6 mg NEXThaler
• Foster 100/6 mg pMDI

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2026-08-10